Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.53
TFX's Cash-to-Debt is ranked lower than
74% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. TFX: 0.53 )
Ranked among companies with meaningful Cash-to-Debt only.
TFX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.17 Max: 0.61
Current: 0.53
0.07
0.61
Equity-to-Asset 0.55
TFX's Equity-to-Asset is ranked lower than
57% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. TFX: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
TFX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.48 Max: 0.55
Current: 0.55
0.32
0.55
Interest Coverage 5.81
TFX's Interest Coverage is ranked lower than
85% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. TFX: 5.81 )
Ranked among companies with meaningful Interest Coverage only.
TFX' s Interest Coverage Range Over the Past 10 Years
Min: 2.18  Med: 3.26 Max: 5.81
Current: 5.81
2.18
5.81
Piotroski F-Score: 7
Altman Z-Score: 4.77
Beneish M-Score: -2.66
WACC vs ROIC
9.71%
11.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 17.10
TFX's Operating Margin % is ranked higher than
86% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. TFX: 17.10 )
Ranked among companies with meaningful Operating Margin % only.
TFX' s Operating Margin % Range Over the Past 10 Years
Min: -6.28  Med: 14.96 Max: 17.46
Current: 17.1
-6.28
17.46
Net Margin % 12.71
TFX's Net Margin % is ranked higher than
84% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. TFX: 12.71 )
Ranked among companies with meaningful Net Margin % only.
TFX' s Net Margin % Range Over the Past 10 Years
Min: -12.25  Med: 11.46 Max: 21.66
Current: 12.71
-12.25
21.66
ROE % 11.31
TFX's ROE % is ranked higher than
75% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. TFX: 11.31 )
Ranked among companies with meaningful ROE % only.
TFX' s ROE % Range Over the Past 10 Years
Min: -10.11  Med: 11.54 Max: 21.44
Current: 11.31
-10.11
21.44
ROA % 6.02
TFX's ROA % is ranked higher than
73% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. TFX: 6.02 )
Ranked among companies with meaningful ROA % only.
TFX' s ROA % Range Over the Past 10 Years
Min: -4.96  Med: 5 Max: 8.55
Current: 6.02
-4.96
8.55
ROC (Joel Greenblatt) % 40.87
TFX's ROC (Joel Greenblatt) % is ranked higher than
83% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. TFX: 40.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TFX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13.25  Med: 31.91 Max: 41.97
Current: 40.87
-13.25
41.97
3-Year Revenue Growth Rate 0.30
TFX's 3-Year Revenue Growth Rate is ranked lower than
66% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. TFX: 0.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TFX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11  Med: 1.5 Max: 14.6
Current: 0.3
-11
14.6
3-Year EBITDA Growth Rate 5.60
TFX's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. TFX: 5.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TFX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.8  Med: 4.5 Max: 14.1
Current: 5.6
-7.8
14.1
3-Year EPS without NRI Growth Rate 12.90
TFX's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. TFX: 12.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TFX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.4  Med: 5.9 Max: 16.1
Current: 12.9
-17.4
16.1
GuruFocus has detected 4 Warning Signs with Teleflex Inc $TFX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TFX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TFX Guru Trades in Q1 2016

George Soros 5,800 sh (New)
Paul Tudor Jones 8,620 sh (New)
Jim Simons 154,100 sh (+279.56%)
Keeley Asset Management Corp 5,255 sh (+65.77%)
Chuck Royce 181,800 sh (unchged)
Murray Stahl 4,792 sh (-3.04%)
Third Avenue Management 38,457 sh (-16.32%)
Joel Greenblatt 25,631 sh (-69.87%)
» More
Q2 2016

TFX Guru Trades in Q2 2016

Ron Baron 104,581 sh (New)
Chuck Royce 181,800 sh (unchged)
George Soros Sold Out
Keeley Asset Management Corp Sold Out
Murray Stahl 4,692 sh (-2.09%)
Third Avenue Management 34,743 sh (-9.66%)
Joel Greenblatt 15,179 sh (-40.78%)
Jim Simons 38,800 sh (-74.82%)
Paul Tudor Jones 2,100 sh (-75.64%)
» More
Q3 2016

TFX Guru Trades in Q3 2016

Paul Tudor Jones 4,350 sh (+107.14%)
Ron Baron 104,581 sh (unchged)
Chuck Royce 181,800 sh (unchged)
Murray Stahl 4,385 sh (-6.54%)
Third Avenue Management 23,102 sh (-33.51%)
Jim Simons 17,400 sh (-55.15%)
Joel Greenblatt 6,646 sh (-56.22%)
» More
Q4 2016

TFX Guru Trades in Q4 2016

Joel Greenblatt 30,267 sh (+355.42%)
Ron Baron 111,702 sh (+6.81%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Third Avenue Management 23,007 sh (-0.41%)
Murray Stahl 4,285 sh (-2.28%)
Chuck Royce 154,200 sh (-15.18%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ALGN, NYSE:VAR, OTCPK:SONVY, OTCPK:SDMHF, OTCPK:CNVVY, OTCPK:CHEOY, NAS:ABMD, OTCPK:WILYY, NAS:MASI, OTCPK:FSPKF, OTCPK:SNNUF, NAS:NUVA, OTCPK:EKTAF, OTCPK:GGNDF, NAS:IART, NAS:WMGI, NYSE:NVRO, NYSE:GMED, NYSE:PEN, NAS:LIVN » details
Traded in other countries:TBH.Germany,
Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Teleflex is a medical technology company that operates in six segments: vascular North America; anesthesia North America; surgical North America; Europe, Middle East, and Africa, or EMEA; Asia; and OEM. The vascular segment sells catheters and other devices used to administer intravenous medications, as well as interventional access products. The anesthesia segment provides airway management and pain management products. The surgical segment sells devices used in surgical procedures, such as ligation and fascial closure systems. The EMEA and Asia segments primarily sell devices used in acute care and surgical settings. The OEM segment supplies devices and instruments to other medical-device manufacturers. Teleflex generates the majority of its revenue in the United States.

Guru Investment Theses on Teleflex Inc

Baron Funds Comments on Teleflex Inc. - Jul 25, 2016

We initiated a position in Teleflex, Inc. (NYSE:TFX), a medical device company that over the past five years has been transformed, under CEO Benson Smith’s leadership, from a diversified industrial company into a pure-play medical device company through a series of divestitures and acquisitions. Today, the company sells products used by hospitals and health care providers for critical care applications and surgical procedures. The company’s products include, among others, catheters that provide vascular access for delivery of intravenous medications, laryngeal masks for delivery of anesthesia, and surgical instruments used for minimally invasive surgery. The company’s products are used in procedures for treatment of acute or life-threatening illnesses and are therefore less susceptible to being cut during an economic downturn.



We think the company has a solid base business that should be able to grow in the mid-single digits on an organic basis driven by volume growth, new product introductions, and to a lesser extent pricing. In addition, we think the company has the potential to accelerate its organic growth through several interesting new product opportunities, including, among others, the Percuvance Surgical System, a surgical instrument for use in minimally invasive procedures. Percuvance requires a smaller incision site than traditional laparoscopic surgery, while maintaining the equivalent rigidity and strength of laparoscopic instruments. Percuvance has the potential to reduce patient trauma and minimize scarring. The company plans to pursue a full market release of the product in the third quarter of 2016. We think the product has widespread application and well over $100 million of revenue potential over the long term.



In addition, the company has several non-revenue dependent margin expansion initiatives in place, including manufacturing plant consolidation, acquisitions of distributors, and material substitution. New product launches at higher margins should also drive margin expansion. We think the combination of organic growth and margin expansion should drive low double-digit earnings growth, with potential for faster earnings growth if new products accelerate the revenue growth rate or management executes accretive acquisitions.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Top Ranked Articles about Teleflex Inc

Baron Funds Comments on Teleflex Inc. Guru stock highlight
We initiated a position in Teleflex, Inc. (NYSE:TFX), a medical device company that over the past five years has been transformed, under CEO Benson Smith’s leadership, from a diversified industrial company into a pure-play medical device company through a series of divestitures and acquisitions. Today, the company sells products used by hospitals and health care providers for critical care applications and surgical procedures. The company’s products include, among others, catheters that provide vascular access for delivery of intravenous medications, laryngeal masks for delivery of anesthesia, and surgical instruments used for minimally invasive surgery. The company’s products are used in procedures for treatment of acute or life-threatening illnesses and are therefore less susceptible to being cut during an economic downturn. Read more...

Ratios

vs
industry
vs
history
PE Ratio 39.04
TFX's PE Ratio is ranked lower than
66% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.89 vs. TFX: 39.04 )
Ranked among companies with meaningful PE Ratio only.
TFX' s PE Ratio Range Over the Past 10 Years
Min: 4.99  Med: 19.47 Max: 39.52
Current: 39.04
4.99
39.52
Forward PE Ratio 23.87
TFX's Forward PE Ratio is ranked lower than
51% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.04 vs. TFX: 23.87 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.04
TFX's PE Ratio without NRI is ranked lower than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. TFX: 39.04 )
Ranked among companies with meaningful PE Ratio without NRI only.
TFX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.97  Med: 26.32 Max: 64.93
Current: 39.04
13.97
64.93
Price-to-Owner-Earnings 31.59
TFX's Price-to-Owner-Earnings is ranked lower than
51% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. TFX: 31.59 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TFX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.84  Med: 19.41 Max: 47.82
Current: 31.59
5.84
47.82
PB Ratio 3.99
TFX's PB Ratio is ranked lower than
57% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. TFX: 3.99 )
Ranked among companies with meaningful PB Ratio only.
TFX' s PB Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.85 Max: 4.05
Current: 3.99
1.04
4.05
PS Ratio 4.96
TFX's PS Ratio is ranked lower than
66% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. TFX: 4.96 )
Ranked among companies with meaningful PS Ratio only.
TFX' s PS Ratio Range Over the Past 10 Years
Min: 0.71  Med: 1.74 Max: 5.03
Current: 4.96
0.71
5.03
Price-to-Free-Cash-Flow 25.97
TFX's Price-to-Free-Cash-Flow is ranked higher than
57% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 29.73 vs. TFX: 25.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TFX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.91  Med: 18.51 Max: 51.54
Current: 25.97
5.91
51.54
Price-to-Operating-Cash-Flow 22.61
TFX's Price-to-Operating-Cash-Flow is ranked lower than
55% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. TFX: 22.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TFX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.22  Med: 14.72 Max: 27.22
Current: 22.61
5.22
27.22
EV-to-EBIT 30.71
TFX's EV-to-EBIT is ranked lower than
62% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. TFX: 30.71 )
Ranked among companies with meaningful EV-to-EBIT only.
TFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.1  Med: 17 Max: 32.7
Current: 30.71
-40.1
32.7
EV-to-EBITDA 22.09
TFX's EV-to-EBITDA is ranked lower than
61% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. TFX: 22.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
TFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -371.3  Med: 12.1 Max: 3794.7
Current: 22.09
-371.3
3794.7
Shiller PE Ratio 45.08
TFX's Shiller PE Ratio is ranked higher than
56% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 54.18 vs. TFX: 45.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
TFX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.95  Med: 20.45 Max: 45.51
Current: 45.08
10.95
45.51
Current Ratio 2.77
TFX's Current Ratio is ranked higher than
59% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. TFX: 2.77 )
Ranked among companies with meaningful Current Ratio only.
TFX' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.91 Max: 4.72
Current: 2.77
1.46
4.72
Quick Ratio 2.03
TFX's Quick Ratio is ranked higher than
57% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. TFX: 2.03 )
Ranked among companies with meaningful Quick Ratio only.
TFX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.2 Max: 3.62
Current: 2.03
0.86
3.62
Days Inventory 139.47
TFX's Days Inventory is ranked lower than
56% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. TFX: 139.47 )
Ranked among companies with meaningful Days Inventory only.
TFX' s Days Inventory Range Over the Past 10 Years
Min: 121.53  Med: 140.15 Max: 171.38
Current: 139.47
121.53
171.38
Days Sales Outstanding 53.15
TFX's Days Sales Outstanding is ranked higher than
71% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. TFX: 53.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
TFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.93  Med: 59.32 Max: 74.92
Current: 53.15
52.93
74.92
Days Payable 29.06
TFX's Days Payable is ranked lower than
79% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. TFX: 29.06 )
Ranked among companies with meaningful Days Payable only.
TFX' s Days Payable Range Over the Past 10 Years
Min: 26.07  Med: 32.72 Max: 42.07
Current: 29.06
26.07
42.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.70
TFX's Dividend Yield % is ranked lower than
77% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.63 vs. TFX: 0.70 )
Ranked among companies with meaningful Dividend Yield % only.
TFX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.69  Med: 1.82 Max: 3.48
Current: 0.7
0.69
3.48
Dividend Payout Ratio 0.27
TFX's Dividend Payout Ratio is ranked higher than
81% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. TFX: 0.27 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TFX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.39 Max: 0.62
Current: 0.27
0.27
0.62
Forward Dividend Yield % 0.70
TFX's Forward Dividend Yield % is ranked lower than
80% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 1.63 vs. TFX: 0.70 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.70
TFX's 5-Year Yield-on-Cost % is ranked lower than
79% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. TFX: 0.70 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TFX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.69  Med: 1.82 Max: 3.48
Current: 0.7
0.69
3.48
3-Year Average Share Buyback Ratio -2.30
TFX's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. TFX: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TFX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.3  Med: -1 Max: 0.8
Current: -2.3
-2.3
0.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.60
TFX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. TFX: 2.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TFX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.12 Max: 2.63
Current: 2.6
0.6
2.63
Price-to-Median-PS-Value 2.86
TFX's Price-to-Median-PS-Value is ranked lower than
94% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. TFX: 2.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TFX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.73 Max: 2.89
Current: 2.86
0.43
2.89
Earnings Yield (Greenblatt) % 3.30
TFX's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. TFX: 3.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TFX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.1  Med: 5.5 Max: 9.4
Current: 3.3
3.1
9.4
Forward Rate of Return (Yacktman) % 0.90
TFX's Forward Rate of Return (Yacktman) % is ranked lower than
72% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.01 vs. TFX: 0.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TFX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.9  Med: 6.85 Max: 19.1
Current: 0.9
0.9
19.1

More Statistics

Revenue (TTM) (Mil) $1,868
EPS (TTM) $ 4.99
Beta1.03
Short Percentage of Float7.41%
52-Week Range $136.53 - 198.89
Shares Outstanding (Mil)44.91

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,075 2,185 2,314
EPS ($) 8.10 10.09 10.65
EPS without NRI ($) 8.10 10.09 10.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 1.35 1.36 1.36
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Teleflex Inc. Jul 25 2016 
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Teleflex (TFX) Announces 510(k) Clearance and Global Launch of Twin-Pass® Torque Dual Access... Mar 14 2017
Teleflex (TFX) Announces 510(k) Clearance and U.S. Launch of Spectre™ Guidewire Mar 14 2017
Moving Average Crossover Alert: Teleflex (TFX) Mar 13 2017
TELEFLEX INC Financials Mar 09 2017
Coverage initiated on Teleflex by Needham Mar 07 2017
Teleflex to Present at Barclays Global Healthcare Conference Feb 28 2017
Teleflex, Inc. :TFX-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017 Feb 27 2017
Teleflex, Inc. :TFX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 24, 2017 Feb 24 2017
Edited Transcript of TFX earnings conference call or presentation 23-Feb-17 1:00pm GMT Feb 23 2017
Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter Feb 23 2017
TELEFLEX INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors... Feb 23 2017
Teleflex Inc Earnings Call scheduled for 8:00 am ET today Feb 23 2017
Q4 2016 Teleflex Inc Earnings Release - Before Market Open Feb 23 2017
Teleflex beats Street 4Q forecasts Feb 23 2017
Teleflex beats Street 4Q forecasts Feb 23 2017
Teleflex Announces Quarterly Dividend Feb 23 2017
Teleflex Reports Fourth Quarter and Full Year 2016 Results; Provides 2017 Guidance Feb 23 2017
Teleflex Incorporated Announces Benson Smith to Retire as Chief Executive Officer at End of 2017;... Feb 23 2017
Teleflex (TFX) Announces 510(k) Clearance and US Launch of TrapLiner™ Catheter Feb 22 2017
MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)